Literature DB >> 29656500

Mitochondria, glycogen, and lipid droplets in skeletal muscle during testosterone treatment and strength training: a randomized, double-blinded, placebo-controlled trial.

R C Jensen1, L L Christensen1, J Nielsen2, H D Schrøder3, T Kvorning2, K Gejl2, K Højlund1, D Glintborg1, M Andersen1.   

Abstract

Low testosterone levels in aging men are associated with insulin resistance. Mitochondrial dysfunction, changes in glycogen metabolism, and lipid accumulation are linked to insulin resistance in skeletal muscle. In this randomized, double-blinded, placebo-controlled study, we investigated the effects of six-month testosterone replacement therapy (TRT) and strength training (ST) on mitochondrial, glycogen, and lipid droplet (LD) content in skeletal muscle of aging men with subnormal bioavailable testosterone (BioT) levels. Mitochondrial, glycogen, and LD volume fractions in muscle biopsies were estimated by transmission electron microscopy. Insulin sensitivity (insulin-stimulated Rd) and body composition were assessed by euglycemic-hyperinsulinemic clamp and dual X-ray absorptiometry, respectively. TRT significantly increased total testosterone levels, BioT, and lean body mass (LBM) (p < 0.05), whereas percent body fat decreased (p < 0.05), and insulin sensitivity was unchanged. Baseline mitochondrial volume fraction correlated inversely with percent body fat (ρ = -0.43; p = 0.003). Δ-mitochondrial fraction correlated positively with Δ-total testosterone (ρ = 0.70; p = 0.02), and Δ-glycogen fraction correlated inversely with Δ-LBM (ρ = -0.83; p = 0.002) during six-month TRT, but no significant changes were observed in mitochondrial, glycogen, and LD volume fractions during TRT and ST. In conclusion, in this exploratory small-scale study, the beneficial effects of six-month TRT on total testosterone, LBM, and percent body fat were not followed by significant changes in fractions of mitochondria, glycogen, or lipid in skeletal muscle of aging men with lowered testosterone levels. Six-month ST or combined three-month ST+TRT did not change intramyocellular mitochondria, glycogen, and LD fractions compared to placebo. However, further studies with a larger sample size are needed.
© 2018 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  metabolism; skeletal muscle; testosterone replacement therapy; transmission electron microscopy

Mesh:

Substances:

Year:  2018        PMID: 29656500     DOI: 10.1111/andr.12492

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  4 in total

1.  Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome.

Authors:  Melanie Cree-Green; Anne-Marie Carreau; Haseeb Rahat; Yesenia Garcia-Reyes; Bryan C Bergman; Laura Pyle; Kristen J Nadeau
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-02-12       Impact factor: 4.310

2.  Efficacy of testosterone replacement therapy for treating metabolic disturbances in late-onset hypogonadism: a systematic review and meta-analysis.

Authors:  Si Hyun Kim; Jae Joon Park; Ki Hong Kim; Hee Jo Yang; Doo Sang Kim; Chang Ho Lee; Youn Soo Jeon; Sung Ryul Shim; Jae Heon Kim
Journal:  Int Urol Nephrol       Date:  2021-06-05       Impact factor: 2.370

3.  Enhanced Skeletal Muscle Oxidative Capacity and Capillary-to-Fiber Ratio Following Moderately Increased Testosterone Exposure in Young Healthy Women.

Authors:  Daniele A Cardinale; Oscar Horwath; Jona Elings-Knutsson; Torbjörn Helge; Manne Godhe; Stéphane Bermon; Marcus Moberg; Mikael Flockhart; Filip J Larsen; Angelica Lindén Hirschberg; Björn Ekblom
Journal:  Front Physiol       Date:  2020-12-03       Impact factor: 4.566

4.  Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men.

Authors:  E Maseroli; P Comeglio; C Corno; I Cellai; S Filippi; T Mello; A Galli; E Rapizzi; L Presenti; M C Truglia; F Lotti; E Facchiano; B Beltrame; M Lucchese; F Saad; G Rastrelli; M Maggi; L Vignozzi
Journal:  J Endocrinol Invest       Date:  2020-08-08       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.